Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future

Niels D Prins and Philip Scheltens

Alzheimer's Research & Therapy 2013, 5:56 (11 November 2013)

Editor-in-Chief Philip Scheltens reviews the monoclonal antibodies designed to clear toxic amyloid-beta from the brain, and discusses what can be learnt from the results of recent phase 3 clinical trials.

Subscription required

All research articles in Alzheimer's Research & Therapy are open access. The journal also publishes a range of other articles that are available to subscribers.

Existing subscribers

Forgotten your password? help